IP Library › Granted Patent US 7,556,820
Granted Patent B2
US 7,556,820 · App. 12/264,517 · Granted Jul 7, 2009

Stable organic peroxide compositions

Assignee: JR Chem, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,556,820
App. No.
12/264,517
Granted
Jul 7, 2009
Kind
B2
Abstract

Benzoyl peroxide compositions are stabilized against decomposition by the use of antioxidants, resulting in increased shelf life of products made using the compositions. Treatment of truncal acne vulgaris with a combination of actives, namely benzoyl peroxide and salicylic acid, is provided via regimens that include applying such benzoyl peroxide compositions to an area of the body afflicted with acne, after a waiting period rinsing the benzoyl peroxide-treated area (e.g., by showering), drying the rinsed area, and then applying a topical, at least partially neutralized salicylic acid composition to the afflicted area.

Claims (10)

1. A method for the treatment of truncal acne vulgaris, the method comprising:

applying a composition containing benzoyl peroxide, an antioxidant and an aryl benzoate ester to an area of the body other than the face afflicted with acne;

waiting a period of time from about 15 seconds to about 20 minutes;

rinsing the benzoyl peroxide-treated area;

drying the rinsed, benzoyl peroxide-treated area; and

applying a topical, at least partially neutralized salicylic acid composition to the dried area.

2. A kit comprising:

at least two separated components (a) and (b) intended to be applied sequentially to an area of a user's skin of afflicted with truncal acne

wherein component (a) is a composition containing benzoyl peroxide, an antioxidant and an aryl benzoate ester and

component (b) is a topical, at least partially neutralized salicylic acid composition.

Assignments (17)
RELEASE OF SECURITY INTEREST Recorded Nov 17, 2025
From: TCW ASSET MANAGEMENT COMPANY LLC, AS ADMINISTRATIVE AGENT
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 072928/0385 →
PATENT SECURITY AGREEMENT Recorded Nov 17, 2025
From: OBAGI COSMECEUTICALS LLC
To: LSSF II OFFSHORE INVESTMENTS, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 073625/0459 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
RELEASE OF SECURITY INTEREST Recorded Mar 21, 2025
From: JPMORGAN CHASE BANK, N.A.
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 070592/0979 →
SECURITY INTEREST Recorded Mar 18, 2025
From: OBAGI COSMECEUTICALS LLC
To: TCW ASSET MANAGEMENT COMPANY LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 070546/0595 →
SECURITY INTEREST Recorded Aug 1, 2022
From: OBAGI COSMECEUTICALS LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 060690/0148 →
RELEASE OF SECURITY INTEREST Recorded Jul 29, 2022
From: TCW ASSET MANAGEMENT COMPANY LLC
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 060668/0771 →
RELEASE OF SECURITY INTEREST Recorded Mar 19, 2021
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 055652/0735 →
SECURITY INTEREST Recorded Mar 16, 2021
From: OBAGI COSMECEUTICALS LLC
To: TCW ASSET MANAGEMENT COMPANY LLC, AS COLLATERAL AGENT
Reel/Frame 055613/0083 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Dec 13, 2018
From: OBAGI COSMECEUTICALS LLC
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 047873/0114 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2017
From: OBAGI MEDICAL PRODUCTS, INC.
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 044829/0092 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Nov 14, 2017
From: BARCLAYS BANK PLC
To: OBAGI MEDICAL PRODUCTS, INC.
Reel/Frame 044750/0475 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Nov 14, 2017
From: BANK OF NEW YORK MELLON
To: OBAGI MEDICAL PRODUCTS, INC.
Reel/Frame 044750/0506 →
SECURITY INTEREST Recorded Jul 19, 2017
From: OBAGI MEDICAL PRODUCTS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043041/0718 →
SECURITY INTEREST Recorded Jul 18, 2016
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSH & LOMB PHARMA HOLDINGS CORP.; DENDREON PHARMACEUTICALS, INC.; DOW PHARMACEUTICAL SCIENCES, INC.; MEDICIS PHARMACEUTICAL CORPORATION; OBAGI MEDICAL PRODUCTS, INC.; OMP, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; SOLTA MEDICAL, INC.; VALEANT CANADA LP, BY ITS GENERAL PARTNER VALEANT CANADA GP LIMITED; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT HOLDINGS IRELAND (AS SUCCESSOR TO VALEANT INTERNATIONAL BERMUDA); VALEANT PHARMACEUTICALS NORTH AMERICA LLC; VALEANT PHARMACEUTICALS IRELAND
To: BARCLAYS BANK PLC
Reel/Frame 039380/0385 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2014
From: JR CHEM, LLC
To: OBAGI MEDICAL PRODUCTS, INC.
Reel/Frame 032033/0235 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2008
From: RAMIREZ, JOSE E.; FARYNIARZ, JOSEPH R.
To: JR CHEM, LLC
Reel/Frame 021943/0968 →
Continuity (4)
Continuation In Part 1198644200 · Nov 21, 2007
Continuation 1147652700 · Jun 28, 2006
Provisional Application 6069522300 · Jun 29, 2005
Related Publication 20090076170A1 · Mar 19, 2009